ILMN - Illumina, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
300.46
-2.74 (-0.90%)
At close: 4:00PM EST

300.46 0.00 (0.00%)
After hours: 4:53PM EST

Stock chart is not supported by your current browser
Previous Close303.20
Open304.00
Bid300.41 x 800
Ask301.00 x 800
Day's Range297.73 - 305.39
52 Week Range263.30 - 380.76
Volume594,242
Avg. Volume1,076,834
Market Cap44.168B
Beta (5Y Monthly)1.15
PE Ratio (TTM)44.58
EPS (TTM)6.74
Earnings DateApr 22, 2020 - Apr 26, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est338.75
  • Where the Bulls Roam: TSLA, ILMN, SQ, NVTA, TTD
    Zacks

    Where the Bulls Roam: TSLA, ILMN, SQ, NVTA, TTD

    Do you know which investment whales were buying and selling your favorite stocks before the big rally to new highs?

  • The Top 5 Buys of Steve Mandel's Lone Pine Capital
    GuruFocus.com

    The Top 5 Buys of Steve Mandel's Lone Pine Capital

    Firm releases its 4th-quarter portfolio Continue reading...

  • Al Gore's Generation Investment Management Buys 4 Stocks in the 4th Quarter
    GuruFocus.com

    Al Gore's Generation Investment Management Buys 4 Stocks in the 4th Quarter

    Former US vice president’s firm releases portfolio Continue reading...

  • Business Wire

    Illumina to Webcast Upcoming Investor Conference Presentations

    SVB Leerink & Cowen Conference Investor Webcasting

  • Pacific Biosciences (PACB) Reports Break-Even Earnings in Q4
    Zacks

    Pacific Biosciences (PACB) Reports Break-Even Earnings in Q4

    Pacific Biosciences (PACB) expects softness in first-quarter consumable sales.

  • Valley startup scores $75M with an eye towards helping track coronavirus
    American City Business Journals

    Valley startup scores $75M with an eye towards helping track coronavirus

    GenapSys said that the new funds will be used for global expansion, particularly in Asia where it says its iPad-sized, next-generation sequencer might be used to help to track the expanding coronavirus outbreak.

  • Illumina, Inc. Just Released Its Yearly Earnings: Here's What Analysts Think
    Simply Wall St.

    Illumina, Inc. Just Released Its Yearly Earnings: Here's What Analysts Think

    Illumina, Inc. (NASDAQ:ILMN) shares fell 9.2% to US$290 in the week since its latest full-year results. Illumina...

  • Illumina, Inc. (NASDAQ:ILMN) Delivered A Better ROE Than Its Industry
    Simply Wall St.

    Illumina, Inc. (NASDAQ:ILMN) Delivered A Better ROE Than Its Industry

    One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

  • Thomson Reuters StreetEvents

    Edited Transcript of ILMN earnings conference call or presentation 29-Jan-20 10:00pm GMT

    Q4 2019 Illumina Inc Earnings Call

  • Mammoth Biosciences aims to be Illumina for the gene editing generation
    TechCrunch

    Mammoth Biosciences aims to be Illumina for the gene editing generation

    In 1998, the startup company Illumina launched a revolution in the life sciences industry by developing technology to slash the costs of identifying and mapping genetic material. Now, a little over 20 years later, Mammoth Biosciences is hoping to do the same thing for gene editing tools. The company, co-founded by Jennifer Doudna, who did some of the pioneering work to discover the gene editing enzyme known as CRISPR, has just raised $45 million as it looks to bring to market products that can be used not only for disease detection, but are more precise editing tools for genetic material.

  • GuruFocus.com

    US Stocks Choppy on Thursday

    Biogen falls on fourth-quarter results Continue reading...

  • Coronavirus update: First U.S. case of person-to-person transmission confirmed, 195 U.S. citizens in isolation and WHO declares a public health emergency
    MarketWatch

    Coronavirus update: First U.S. case of person-to-person transmission confirmed, 195 U.S. citizens in isolation and WHO declares a public health emergency

    A new U.S. task force led by Health and Human Services chief Alex Azar is the latest effort by officials to prepare for additional cases of the novel coronavirus in the U.S.

  • Coronavirus: How Fast to 100,000 Infected?
    Zacks

    Coronavirus: How Fast to 100,000 Infected?

    The current geometric rate of transmission implies that over 100,000 people could be infected by early February.

  • Illumina (ILMN) Q4 Earnings Beat Estimates, Margins Expand
    Zacks

    Illumina (ILMN) Q4 Earnings Beat Estimates, Margins Expand

    Illumina (ILMN) exhibits robust growth in the fourth quarter of fiscal 2019, fueled by strong performance of the sequencing consumable segment.

  • Illumina (ILMN) Q4 Earnings and Revenues Top Estimates
    Zacks

    Illumina (ILMN) Q4 Earnings and Revenues Top Estimates

    Illumina (ILMN) delivered earnings and revenue surprises of 6.92% and 0.63%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

  • DNA Testing Behemoth Illumina Slips As 2020 Outlook Comes Up Short
    Investor's Business Daily

    DNA Testing Behemoth Illumina Slips As 2020 Outlook Comes Up Short

    Late Wednesday, Illumina reported adjusted earnings of $1.70 per share on $953 million in sales for its fourth quarter ended Dec. 29. The results prodded ILMN stock down a fraction.

  • Coronavirus: Epidemic or Pandemic?
    Zacks

    Coronavirus: Epidemic or Pandemic?

    The current geometric rate of transmission implies that over 100,000 people could be infected by early February.

  • Business Wire

    Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2019

    Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year 2019.

  • Illumina Earnings, Revenue Beat in Q4
    Investing.com

    Illumina Earnings, Revenue Beat in Q4

    Investing.com - Illumina (NASDAQ:ILMN) reported on Wednesday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations.

  • Benzinga

    The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 28) 10X Genomics Inc (NASDAQ: TXG ) Acceleron Pharma Inc ...

  • Once-hot DNA testing unicorn 23andMe is in serious trouble
    Yahoo Finance

    Once-hot DNA testing unicorn 23andMe is in serious trouble

    After a 2018 boom, people are just not buying DNA kits anymore.

  • Bloomberg

    Big Tech Gets Put on Guard by Antitrust Police

    (Bloomberg Opinion) -- When the world’s competition police reflect on big tech’s dealmaking over the past 15 years, you could forgive them for wondering what might have been. If Facebook Inc. hadn’t acquired WhatsApp or Instagram, or if Google hadn’t bought YouTube or DoubleClick, would there be stronger competition for the two Silicon Valley firms?It certainly seems that regulators, particularly in the U.K., are eager to avoid repeat scenarios where companies grab outsize control of an emerging market before it’s clear exactly how important or big that market may be. That’s why a 6.1 billion-pound ($8 billion) food delivery takeover may have broader implications for tech giants’ dealmaking-to-come.Britain’s Competition and Markets Authority is reviewing the Dutch firm Takeaway.com NV’s planned acquisition of Just Eat Plc, the U.K.’s online marketplace for restaurant delivery. It’s a remarkable step, given that Takeaway.com no longer has a British business, and so the two firms don’t currently compete, at least not in the U.K. The regulator, the CMA, is instead pondering hypotheticals. It’s deliberating whether, without a deal, Takeaway.com might still otherwise enter the market and add a healthy dose of competition.The move underscores a recent approach that could make it more difficult for tech giants to make acquisitions, even small ones. (Together, they’ve bought more than 250 companies in the last six years.) Companies might not obviously compete with the firm acquiring them, but the U.K. watchdog is increasingly taking into account the possibility they could become a competitor at some later stage. It seems to have listened to the findings of the government-commissioned review into digital competition last year by Jason Furman, previously economic adviser to former U.S. President Barack Obama, which recommended that the CMA should take “more frequent and firmer action to challenge mergers that could be detrimental to consumer welfare through reducing future levels of innovation and competition.”Across the Atlantic, DNA-sequencing firm Illumina Inc.’s scuppered $1.2 billion acquisition of smaller peer Pacific Biosciences of California Inc. also illustrates the challenge. Both firms are active in slightly different parts of the market, so do not directly compete: Illumina currently focuses on so-called short-read sequencing platforms, while PacBio’s expertise is in long-reads. Yet antitrust authorities in both the U.K. and U.S. pushed back against the deal because of concerns that Illumina would decide against developing its own long-read offering further down the line, according to Bloomberg Intelligence analyst Aitor Ortiz. The firms called the deal off earlier this month.It’s healthy that technology deals are likely to attract more scrutiny. Acquisitions sometimes look like a catch-and-kill strategy: buying a startup that could become a rival before it's able to do so without necessarily using it to augment the business directly. For example, back in 2017, Facebook bought the fast-growing teen app tbh, before shutting it down just eight months later, citing low usage.But doing so presents a potential challenge for the CMA: ensuring that the U.K. remains an attractive place to found technology firms. Venture capitalists and big companies themselves often argue that a lot of startups are founded with the intention of ultimately selling themselves to a larger rival. If that exit strategy disappears, runs the argument, then they might decide to set up shop elsewhere.So far, it’s too early to determine whether that argument has any merit. And analysts still expect the Takeaway.com-Just Eat deal to complete, albeit with a slight delay. But because the CMA has the authority to impose remedies without a court case, unlike the U.S.’s Federal Trade Commission, technology firms have good reason to be wary.To contact the author of this story: Alex Webb at awebb25@bloomberg.netTo contact the editor responsible for this story: Melissa Pozsgay at mpozsgay@bloomberg.netThis column does not necessarily reflect the opinion of Bloomberg LP and its owners.Alex Webb is a Bloomberg Opinion columnist covering Europe's technology, media and communications industries. He previously covered Apple and other technology companies for Bloomberg News in San Francisco.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Benzinga

    The Week Ahead In Biotech: Amgen, Eli Lilly, Pfizer In Earnings Mix, IPO Flow Resumes

    Biotech stocks haven't seen much of a momentum thus far in the new year amid a lack of meaningful catalysts. The bygone week saw two FDA approvals:  Horizon Therapeutics PLC's (NASDAQ: HZNP ) thyroid eye ...

  • Can Sequencing Products Aid Illumina (ILMN) in Q4 Earnings?
    Zacks

    Can Sequencing Products Aid Illumina (ILMN) in Q4 Earnings?

    Illumina (ILMN) is upbeat about fourth-quarter and fiscal 2019 results after a strong third-quarter performance.